16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis

PHASE3CompletedINTERVENTIONAL
Enrollment

371

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Secukinumab (75 mg)

Secukinumab (75 mg)

DRUG

Secukinumab (150 mg)

Secukinumab (150 mg)

DRUG

Placebo

Placebo

Trial Locations (67)

11

Novartis Investigative Site, Jesus Maria

13

Novartis Investigative Site, La Victoria

21

Novartis Investigative Site, Pueblo Libre

27

Novartis Investigative Site, San Isidro

34

Novartis Investigative Site, Surquillo

1200

Novartis Investigative Site, Brussels

1431

Novartis Investigative Site, Sofia

1612

Novartis Investigative Site, Sofia

3000

Novartis Investigative Site, Leuven

3600

Novartis Investigative Site, Genk

4000

Novartis Investigative Site, Plovdiv

4002

Novartis Investigative Site, Plovdiv

8000

Novartis Investigative Site, Burgas

9000

Novartis Investigative Site, Ghent

10126

Novartis Investigative Site, Torino

12203

Novartis Investigative Site, Berlin

16635

Novartis Investigative Site, Duncansville

21100

Novartis Investigative Site, Mexicali

22143

Novartis Investigative Site, Hamburg

22415

Novartis Investigative Site, Hamburg

25123

Novartis Investigative Site, Brescia

27310

Novartis Investigative Site, Gaziantep

33076

Novartis Investigative Site, Bordeaux

34098

Novartis Investigative Site, Fatih / Istanbul

35340

Novartis Investigative Site, Balcova / Izmir

37067

Novartis Investigative Site, Valeggio sul Mincio

37660

Novartis Investigative Site, Kingsport

38305

Novartis Investigative Site, Jackson

39110

Novartis Investigative Site, Magdeburg

40201

Novartis Investigative Site, Taichung

40882

Novartis Investigative Site, Ratingen

44160

Novartis Investigative Site, Guadalajara

44649

Novartis Investigative Site, Herne

50924

Novartis Investigative Site, Cologne

53100

Novartis Investigative Site, Siena

64020

Novartis Investigative Site, Monterrey

75014

Novartis Investigative Site, Paris

75231

Novartis Investigative Site, Dallas

76126

Novartis Investigative Site, Benbrook

78731

Novartis Investigative Site, Austin

80000

Novartis Investigative Site, Culiacán

81346

Novartis Investigative Site, Kaohsiung City

83702

Novartis Investigative Site, Boise

87001

Novartis Investigative Site, Limoges

90127

Novartis Investigative Site, Palermo

90429

Novartis Investigative Site, Nuremberg

91054

Novartis Investigative Site, Erlangen

95100

Novartis Investigative Site, Catania

97239

Novartis Investigative Site, Portland

99204

Novartis Investigative Site, Spokane

115522

Novartis Investigative Site, Moscow

150003

Novartis Investigative Site, Yaroslavl

197341

Novartis Investigative Site, Saint Petersburg

300053

Novartis Investigative Site, Tula

620028

Novartis Investigative Site, Yekaterinburg

620102

Novartis Investigative Site, Yekaterinburg

52401-2112

Novartis Investigative Site, Cedar Rapids

R3A 1M3

Novartis Investigative Site, Winnipeg

A1C 5B8

Novartis Investigative Site, St. John's

M5T 2S8

Novartis Investigative Site, Toronto

07740

Novartis Investigative Site, Jena

1105 AZ

Novartis Investigative Site, Amsterdam

3584 CX

Novartis Investigative Site, Utrecht

E11 1NR

Novartis Investigative Site, London

CB2 2QQ

Novartis Investigative Site, Cambridge

NE1 4LP

Novartis Investigative Site, Newcastle upon Tyne

WV10 0QP

Novartis Investigative Site, Wolverhampton

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY